This demonstration study will evaluate the real-world implementation of long-acting cabotegravir (CAB-LA) for HIV pre-exposure prevention (PrEP) through a partnership between the OHSU Tele-PrEP Program (TPP) and the OHSU Home Infusion Pharmacy (HIP). The study will perform a formative evaluation of the TPP/HIP partnership to determine its merit and worth, with revisions made as needed to improve the program, which is reflective of a real-world program rollout. The study is observational, and there is no comparison group. The primary objective is to evaluate adherence to CAB-LA by both urban and rural participants using the TPP/HIP partnership. The goals of the study are improve the TPP/HIP program itself with attention to reducing geographic disparities, and to disseminate best practices and lessons learned to the broader HIV prevention community.

Inclusion Criteria:

• Residence in Oregon
• English or Spanish spoken and written language ability
• Clinical eligibility for PrEP with CAB-LA including HIV-negative serostatus
• Access to stable Internet
• Access to a clean, safe location that is appropriate for home administration

Exclusion Criteria:

• Clinical ineligibility for PrEP with CAB-LA including HIV-positive serostatus, injection drug use as only HIV risk factor, or clinical contraindication (such as a hypersensitivity reaction to CAB-LA or use of a contraindicated medication).
• Uninsured
• Payer does not cover HIP services
• Pregnancy
• Residence outside of the home infusion program's catchment area
• Incarceration
• Decisional impairment

All genders are eligible

Residents of Oregon age 18 or older who are eligible for HIV pre-exposure prophylaxis with long-acting cabotegravir through the OHSU Tele-PrEP Program and OHSU Home Infusion Pharmacy. People of childbearing potential or who are breast/chest feeding are eligible, but pregnant people are ineligible.

De-identified individual participant data and adverse event reporting will be shared with the study partner ViiV Healthcare.